Equity Overview
Price & Market Data
Price: $1.01
Daily Change: +$0.03 / 2.97%
Daily Range: $1.00 - $1.01
Market Cap: $20,349,014
Daily Volume: 100
Performance Metrics
1 Week: -9.26%
1 Month: -15.52%
3 Months: -19.67%
6 Months: -52.66%
1 Year: -5.77%
YTD: -45.86%
Company Details
Employees: 16
Sector: Health technology
Industry: Biotechnology
Country:
Details
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.